Performance of a new risk assessment tool for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the targeted therapy era: REMARCC score

Performance of a new risk assessment tool for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the targeted therapy era: REMARCC score

Bibliographic Details
Main Authors: M.C. Mir Maresma, M. Marchioni, R. Campi, A. Minervini, M. Kriegmair, M. Heck, F. Porpiglia, S. Van Bruwaene, E. Linares, V. Hevia, M. Musquera, I. Derweesh, F. Ghali, R. Autorino, A. Veccia, E. Roussel, M. Albertsen, N. Pavan, A. Antonellia, C. Palumbo, U. Capitanio, T. Klatte, S. Erdem, J. Rubio-Briones
Format: Article
Language:English
Published: Elsevier 2020-07-01
Series:European Urology Open Science
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168320334340
Description
ISSN:2666-1683

Similar Items